| Project/Area Number |
22500398
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory animal science
|
|---|
| Research Institution | National Institute of Health Sciences |
|---|
Principal Investigator |
KITAJIMA Satoshi 国立医薬品食品衛生研究所, 安全性生物試験研究センター, 毒性部第五室室長 (30270622)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 安全性 / 催奇形性 / トキシコゲノミクス / マウス胚 |
|---|
| Research Abstract |
Thalidomide, a sedative originally used and now used for the treatment of multiple myeloma, is one of the most famous teratogen that causes birth defects such as limb truncations in humans. The teratogenic effect of thalidomide is strictly species specific, i.e. mice and rats are resistant upon thalidomide exposure. In order to seek the molecular mechanism on this species difference of the thalidomide-induced phocomelia, we attempt to examine three point-time series of comprehensive gene-expression analysis for 1,000 mg/kg thalidomide-exposed mouse embryo in the case of both the whole embryo at 7.5 dpc and the hindlimb bud at 10.5 dpc, As a result, two candidate transcription factors were identified, and the teratogenicity experiment using the activator and/or inhibitor of the related signal network are now in progress, in order to verify these candidate genes.
|
